Contributing Member of the Healthcare Councils

GLG News by this Author

Vaccinate Both Genders Against HPV

March 30, 2009

Analysis of:A Vaccine Debate Once Focused on Sex Shifts as Boys Join the Target Market | www.washingtonpost.com

A Vaccine Debate Once Focused on Sex Shifts as Boys Join the Target Market | www.washingtonpost.com (view article) As  the vaccine protects the men it is obvious it protects their women partners and a chain of infection is borken.  This is axiomatic in contact infection control.  Surgeon General Parran demonstrated this a long time ago.

AXX100

February 11, 2009

Analysis of:Capstone Therapeutics Announces Initiation of Dosing for AZX100 Phase 2 Clinical Trial in Dermal Scarring; Management to Host Teleconference and Webcast Today | www.msnbc.msn.com

YEARS OF DOING SKIN SURGERY, TREATING KELOIDS IN PATIENTS HAVE DEMONSTRATED A NEED FOR A KELOID PREVENTING MODALITY.  AZX100 SHOULD BE STUDIED, IF IT HAS NOT ALREADY BEEN, IN PATIENTS PRONE TO KEOIDS WHO NEED FURTHER SKIN SURGERY.  THIS GIVE US AN EXCELLENT REPRODUCIBLE CLINICAL MODEL WITH A VISIBLE AND CONTROLLED END POINT.     

NOT ALL DERMAL FILLERS ARE CREATED EQUAL

February 10, 2009

Analysis of:FDA Faults Wrinkle Fillers Over Warnings | online.wsj.com

SINCE THE CHEMICAL COMPOSITION OF DERMAL FILLERS VARIES THE CONCERNS SHOULD VARY.  INDEED THE SIDE EFFECTS THAT HAVE OCCURRED HAVE BEEN DIFFERED BY COMPOSITION OF THE FILLER.

Ustekinumab-new drug that gets to the core of psoriasis

December 19, 2007

Analysis of:Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis | www.jnj.com

This is exciting news in that P40 is a protein central to the pathogenesis of psoriasis and now utilizing this basic science knowledge long term remission of psoriasis, and inflammatory arthritis has occurred.  The good news is out. However, this is the first use of IL12/23 in human disease now we await side effects, short-term and long-term.  In animal studies P40 inhibition led to an incidence of infection, including granulomatous infections, e.g. tuberculosis. We await more data. Robert Auerbach, MD

Cost is the most critical factor in patient's decision to use Botox and soon Reloxin

December 14, 2007

Analysis of:Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com

Medicis is widely respected by dermatologists who will have confidence in Reloxin because Medicis is marketing the product.  Price of using these modalities will decrease and use will increase.  As patients are happier the word will spread and use will increase even further.

PROPER USES OF TOPICAL ANTIBIOTICS, SEE BELOW

April 23, 2007

Analysis of:FDA Approves Antibiotic Ointment For Children And Adults - Altabax (retapamulin Ointment) | www.medicalnewstoday.com

WHAT ARE THE PROPER USES OF ANTIBIOTICS ON INFECTED SITES, "CLEAN SITES", POST-OP SITES, ETC.?
AN ANALYSIS OF TODAY'S THINKING.
FOR IMPETIGO IT WILL BE USED, IT WILL NOT REPLACE EXISTING MODALITIES, BUT WILL SUPPLEMENT, AND HAVE THE ADVANTAGE OF NOT BEING USED SYSTEMICALLY.
ROBERT AUERBACH, MD

ANOTHER FILLER, PROS AND CONS

April 23, 2007

Analysis of:Anika Gets CE Mark Certification For Commercial Sale Of Cosmetic Dermatology Product, ELEVESS In European Union | www.tradingmarkets.com

IT MAY LAST LONGER, PROBABLY MORE EXPENSIVE, INJECTION TECHNIQUE MAY BE MORE CRITICAL IF IT LAST LONGER, I.E. MORE VISCOUS LESS MALLEABLE.  HOW MUCH CLINICAL DATA IS AVAILABLE?
HAVING USED FILLER MATERIAL FOR OVER 25 YEARS I HAVE EXPERIENCE WITH ALL OF THEM LONG-TERM.
ROBERT AUERBACH, MD

Page : 11 to 7 of 7